Cyclacel Pharmaceuticals (NASDAQ:CYCC) Receives New Coverage from Analysts at StockNews.com

Research analysts at StockNews.com assumed coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC – Get Rating) in a research note issued on Wednesday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Separately, Oppenheimer decreased their price objective on Cyclacel Pharmaceuticals from $10.00 to $8.00 and set an “outperform” rating for the company in a research note on Tuesday, March 7th.

Cyclacel Pharmaceuticals Stock Performance

NASDAQ CYCC opened at $0.68 on Wednesday. The stock has a fifty day moving average of $0.60 and a 200-day moving average of $0.78. The stock has a market capitalization of $8.50 million, a P/E ratio of -0.35 and a beta of 1.11. Cyclacel Pharmaceuticals has a 52 week low of $0.50 and a 52 week high of $2.41.

Cyclacel Pharmaceuticals (NASDAQ:CYCC – Get Rating) last released its earnings results on Monday, March 6th. The biotechnology company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.12). Equities research analysts forecast that Cyclacel Pharmaceuticals will post -1.72 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Cyclacel Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. HRT Financial LP acquired a new stake in shares of Cyclacel Pharmaceuticals during the fourth quarter worth $27,000. Virtu Financial LLC acquired a new stake in shares of Cyclacel Pharmaceuticals during the second quarter worth $33,000. Kestra Advisory Services LLC acquired a new stake in shares of Cyclacel Pharmaceuticals during the third quarter worth $34,000. Renaissance Technologies LLC bought a new position in Cyclacel Pharmaceuticals during the second quarter worth about $68,000. Finally, Two Sigma Investments LP bought a new position in Cyclacel Pharmaceuticals during the third quarter worth about $98,000. 23.77% of the stock is owned by institutional investors and hedge funds.

About Cyclacel Pharmaceuticals

(Get Rating)

Cyclacel Pharmaceuticals, Inc is a clinical stage biopharmaceutical company. It uses cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. The company builds a biopharmaceutical business, which is focused in hematology and oncology based on a pipeline of novel drug candidates.